Company Analysis
Sign in

Axsome Therapeutics, Inc. (AXSM)

Nasdaq: AXSM · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2013
Full chart Alerts Compare
Grade6.2
◀ Past 7.0● Present 6.1▶ Future 5.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

169 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Axsome Therapeutics, Inc.’s names, not what it holds today.

Patents granted
169
169 utility, 1976 to Dec 31, 2025
Granted in 2025
18
Against 24 in 2024 and 29 in 2023
Applications published
234
39 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals121
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
AXSOME THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
195 published
AXSOME THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
134 granted
3 published
Axsome Malta Ltd. a subsidiary
named as the applicant on its applications, in MT
0 granted
36 published
AXSOME MALTA LTD. a subsidiary
MT, as the owner printed on each patent
35 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,485,176Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 25, 202512,478,678Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 18, 202512,472,258Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 18, 202512,472,257Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 18, 202512,472,256Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 18, 202512,472,255Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Oct 21, 202512,447,155Use of reboxetine to treat narcolepsyPharmaceuticalsAXSOME THERAPEUTICS, INC.
Aug 19, 202512,390,419Formulations of (R)-2-amino-3-phenylpropyl carbamatePharmaceuticalsAXSOME MALTA LTD.
Aug 12, 202512,384,743Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereofPharmaceuticalsAXSOME MALTA LTD.
Jul 29, 202512,370,196Pharmaceutical compositions comprising meloxicamPharmaceuticalsAXSOME THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387349COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOFPharmaceuticalsAXSOME THERAPEUTICS, INC.
Dec 4, 20252025/0367121DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTSPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 27, 20252025/0360107USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERSPharmaceuticalsAXSOME THERAPEUTICS, INC.
Nov 20, 20252025/0352476FORMULATIONS OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATEPharmaceuticalsAxsome Malta Ltd.
Nov 6, 20252025/0340509COMPOSITIONS COMPRISING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AND USES THEREOFOrganic fine chemistryAxsome Malta Ltd.
Nov 6, 20252025/0339538PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEPharmaceuticalsAXSOME THERAPEUTICS, INC.
Oct 30, 20252025/0332172PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMPharmaceuticalsAXSOME THERAPEUTICS, INC.
Oct 2, 20252025/0302969PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINEPharmaceuticalsAXSOME THERAPEUTICS, INC.
Oct 2, 20252025/0302844PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMPharmaceuticalsAXSOME THERAPEUTICS, INC.
Sep 25, 20252025/0295785PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMPharmaceuticalsAXSOME THERAPEUTICS, INC. · patent 12,472,258 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 69 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AXSM · research, not advice